Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for XXXX .

@entity1 @entity7139 @entity12188 @entity2590 @entity3052 @entity1503 @entity309
Donor lymphocyte infusion has become established as a salvage therapy for @entity1 with @entity1503 relapsing after allogeneic bone marrow transplantation (BMT). The role of donor lymphocyte infusion for @entity1 with @entity2590 ( @entity2590 ) remains to be established. Between July 1993 and October 2001, 14 @entity1 with @entity2590 relapsing after allogeneic BMT received DLI as salvage therapy. At the time of BMT, one @entity1 had @entity309 , nine had @entity7139 , of whom three were in CR after induction-type chemotherapy, two had @entity7139 , one had @entity12188 and one had @entity3052 . Donors were HLA-matched siblings (n=12), HLA-matched other relative (n=1) and unrelated (n=1). At the time of relapse, the median marrow blast count was 9%. The median CD3+ cell dose administered was 6.3 x 10(7)/kg. With a median follow-up of 49 months, six @entity1 were alive, of whom two were in CR after DLI alone and remained disease-free, two were in CR after a second BMT and two had active disease. Eight @entity1 died of disease progression. Although DLI alone seems to be effective in a small number of @entity1 with @entity2590 , other treatment strategies, including prior debulking chemotherapy, deserve investigation.
